首页> 外文期刊>Biomaterials Science >Tetrazine-mediated bioorthogonal removal of 3-isocyanopropyl groups enables the controlled release of nitric oxide in vivo
【24h】

Tetrazine-mediated bioorthogonal removal of 3-isocyanopropyl groups enables the controlled release of nitric oxide in vivo

机译:四嗪介导的3-异氰丙基丙基的生物正交除去能够在体内控制释放一氧化物

获取原文
获取原文并翻译 | 示例
           

摘要

Bond cleavage bioorthogonal chemistry has been widely employed to restore or activate proteins or prodrugs. Nitric oxide (NO), as a free radical molecule, has joined the clinical arena of cancer therapy, since high levels of NO could produce a cancer cell growth inhibitory effect. However, the spatiotemporal controlled release of NO remains a great challenge, and bioorthogonal chemistry may open a new window. Herein, we described a class of O~2-3-isocyanopropyl diazeniumdiolates 3a-f as new bioorthogonal NO precursors, which can be effectively uncaged via tetrazine-mediated bond cleavage reactions to liberate NO and acrolein in living cancer cells, exhibiting potent antiproliferative activity. Furthermore, 3a and tetrazine BTZ were respectively encapsulated into two liposomes. It was found that simultaneous administrations of the two liposomes could specifically release large amounts of NO in the implanted cancer cells in zebrafish, thus generating potent tumor suppression activity in vivo. Our findings indicate that the TZ-labile NO precursors could serve to expand the NO-based smart therapeutics and the scope of bioorthogonal chemistry utility in vivo in the near future.
机译:粘合性裂解生物正交化化学已被广泛用于恢复或激活蛋白质或前药。作为自由基分子的一氧化氮(NO)已加入癌症治疗的临床竞技场,因为高水平的NO可能产生癌细胞生长抑制作用。然而,不留下的时空控制释放仍然是一个巨大的挑战,生物正交化学可能会打开一个新窗口。在此,我们描述了一类O〜2-3-异氰丙基二齐甲酸盐3a-F作为新的生物正交无前体,其可以通过四嗪介导的粘附反应有效地未探测在生物癌细胞中释放NO和丙烯醛,表现出有效的抗增殖活性。此外,3A和四嗪BTZ分别包封成两个脂质体。结果发现,两种脂质体的同时施用可以在斑马鱼的植入癌细胞中特别释放大量的否,从而在体内产生有效的肿瘤抑制活性。我们的研究结果表明,TZ-Libile在不久的将来,无法扩大基于无智能治疗方法和体内生物正交化学效用的范围。

著录项

  • 来源
    《Biomaterials Science》 |2021年第5期|共10页
  • 作者单位

    State Key Laboratory of Pathogenesis Prevention and Treatment of High Incidence Diseases in Central Asia Xinjiang Medical University Urumqi 830054 P.R. China;

    State Key Laboratory of Pathogenesis Prevention and Treatment of High Incidence Diseases in Central Asia Xinjiang Medical University Urumqi 830054 P.R. China;

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases China Pharmaceutical University Nanjing 210009 P.R. China;

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases China Pharmaceutical University Nanjing 210009 P.R. China;

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases China Pharmaceutical University Nanjing 210009 P.R. China;

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases China Pharmaceutical University Nanjing 210009 P.R. China;

    School of Pharmacy Nantong University Nantong 226001 P.R. China;

    State Key Laboratory of Pathogenesis Prevention and Treatment of High Incidence Diseases in Central Asia Xinjiang Medical University Urumqi 830054 P.R. China;

    National-certified Enterprise Technology Center Disha Pharmaceutical Group Co. Ltd. Weihai 264205 P.R. China;

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases China Pharmaceutical University Nanjing 210009 P.R. China;

    State Key Laboratory of Pathogenesis Prevention and Treatment of High Incidence Diseases in Central Asia Xinjiang Medical University Urumqi 830054 P.R. China;

    State Key Laboratory of Pathogenesis Prevention and Treatment of High Incidence Diseases in Central Asia Xinjiang Medical University Urumqi 830054 P.R. China;

    State Key Laboratory of Pathogenesis Prevention and Treatment of High Incidence Diseases in Central Asia Xinjiang Medical University Urumqi 830054 P.R. China;

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases China Pharmaceutical University Nanjing 210009 P.R. China;

    State Key Laboratory of Pathogenesis Prevention and Treatment of High Incidence Diseases in Central Asia Xinjiang Medical University Urumqi 830054 P.R. China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 计量学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号